U.K. fund manager Schroders, a large shareholder in the U.K. pharmaceutical company, urged it to reopen talks with Pfizer over the 69.4 billion pound takeover, saying it was disappointed they had come to a "premature" end, the Financial Times reports.
Several shareholders expressed disappointment with the decision and Schroders is the biggest so far to vent its feelings publicly. The firm also aimed its ire at Pfizer for its part in the deal breakdown, the Times said.
TheStreet Ratings team rates ASTRAZENECA PLC as a Buy with a ratings score of B-. TheStreet Ratings Team has this to say about their recommendation:
"We rate ASTRAZENECA PLC (AZN) a BUY. This is driven by a number of strengths, which we believe should have a greater impact than any weaknesses, and should give investors a better performance opportunity than most stocks we cover. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income."